Analysis of TCGA and HPA data demonstrated that IDH wild-type (IDHwt) GBM patients with ERVK3-1 expression greater than 3.3 fragments per kilobase of transcript per million mapped reads (fpkm) had significantly lower median overall survival (OS) relative to patients with ERVK3-1 expression less than 3.3 fpkm (18.3 vs. 15.1 months, p = 0.039). Here, ERVK3-1 is linked to glioblastoma.